Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.610
-0.020 (-3.17%)
At close: Apr 28, 2026, 4:00 PM EDT
0.604
-0.006 (-0.95%)
After-hours: Apr 28, 2026, 4:45 PM EDT
Barinthus Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | - | 14.97 | 0.8 | 44.7 | 0.27 | Upgrade
|
| Revenue Growth (YoY) | - | 1766.46% | -98.21% | 16580.22% | -94.44% | Upgrade
|
| Cost of Revenue | 0.13 | 1.68 | 2.01 | 42.35 | 20.37 | Upgrade
|
| Gross Profit | -0.13 | 13.29 | -1.21 | 2.35 | -20.1 | Upgrade
|
| Selling, General & Admin | 35.01 | 23.54 | 39.79 | 6.47 | 25.12 | Upgrade
|
| Research & Development | 23.43 | 36.57 | 39.4 | -1.24 | -4 | Upgrade
|
| Other Operating Expenses | -0.51 | -1.18 | - | - | - | Upgrade
|
| Operating Expenses | 57.94 | 58.94 | 79.19 | 5.23 | 21.12 | Upgrade
|
| Operating Income | -58.07 | -45.65 | -80.4 | -2.87 | -41.22 | Upgrade
|
| Interest Expense | -0.05 | -0.05 | -0.03 | -0.02 | -2.67 | Upgrade
|
| Interest & Investment Income | 1.96 | 2.68 | 2.88 | 3.1 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | 0.21 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.02 | 0.14 | 1.08 | 0.57 | 6.33 | Upgrade
|
| EBT Excluding Unusual Items | -56.15 | -42.89 | -76.47 | 0.78 | -37.35 | Upgrade
|
| Impairment of Goodwill | - | -12.21 | - | - | - | Upgrade
|
| Asset Writedown | -10.46 | -5.26 | - | - | - | Upgrade
|
| Other Unusual Items | -0.03 | -0.87 | -0.06 | 0.07 | -13.79 | Upgrade
|
| Pretax Income | -66.63 | -61.23 | -76.52 | 0.85 | -51.14 | Upgrade
|
| Income Tax Expense | -0.18 | -0.04 | -3.08 | -4.47 | -0.03 | Upgrade
|
| Earnings From Continuing Operations | -66.46 | -61.18 | -73.45 | 5.32 | -51.11 | Upgrade
|
| Minority Interest in Earnings | 0.03 | 0.11 | 0.1 | 0.02 | 0.25 | Upgrade
|
| Net Income | -66.43 | -61.07 | -73.35 | 5.34 | -50.87 | Upgrade
|
| Net Income to Common | -66.43 | -61.07 | -73.35 | 5.34 | -50.87 | Upgrade
|
| Shares Outstanding (Basic) | 41 | 39 | 38 | 37 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 41 | 39 | 38 | 38 | 26 | Upgrade
|
| Shares Change (YoY) | 3.00% | 2.50% | 0.57% | 47.40% | 227.59% | Upgrade
|
| EPS (Basic) | -1.64 | -1.55 | -1.91 | 0.14 | -1.96 | Upgrade
|
| EPS (Diluted) | -1.64 | -1.55 | -1.91 | 0.14 | -1.96 | Upgrade
|
| Free Cash Flow | -48.02 | -29.83 | -56.34 | -20.57 | -33.73 | Upgrade
|
| Free Cash Flow Per Share | -1.19 | -0.76 | -1.47 | -0.54 | -1.30 | Upgrade
|
| Gross Margin | - | 88.78% | -150.75% | 5.26% | - | Upgrade
|
| Operating Margin | - | -304.98% | -10024.69% | -6.43% | -15380.60% | Upgrade
|
| Profit Margin | - | -408.00% | -9145.51% | 11.95% | -18979.48% | Upgrade
|
| Free Cash Flow Margin | - | -199.29% | -7024.69% | -46.01% | -12585.45% | Upgrade
|
| EBITDA | -55.22 | -43.05 | -78.17 | -1.75 | -40.82 | Upgrade
|
| EBITDA Margin | - | -287.61% | - | -3.92% | - | Upgrade
|
| D&A For EBITDA | 2.85 | 2.6 | 2.23 | 1.12 | 0.4 | Upgrade
|
| EBIT | -58.07 | -45.65 | -80.4 | -2.87 | -41.22 | Upgrade
|
| EBIT Margin | - | - | - | -6.43% | - | Upgrade
|
| Revenue as Reported | - | 14.97 | 0.8 | 44.7 | 0.27 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.